Evidence on the ARRIVE Trial and Elective Induction at 39 Weeks

preview_player
Показать описание
Join Dr. Rebecca Dekker and EBB Research Fellow Morgan Richardson Cayama as we explore the ARRIVE Trial and its impact on elective induction at 39 weeks. Together, we'll break down what elective induction involves, examine the trial's findings and critiques, and discuss the latest evidence on this increasingly common practice. Elective inductions have surged since the Trial's release. In this podcast episode, we'll talk about the latest post-ARRIVE research, and the benefits, risks, and professional guidelines on elective induction at 39 weeks. Additionally, we'll focus on the crucial role of respectful maternity care when making decisions about induction.

Рекомендации по теме
Комментарии
Автор

A large retrospective study (before ARRIVE trial) is needed i think. This study has very significant biases

missdbrown